Loncar Cancer Immunotherapy ETF (CNCR)

Delayed Data
As of 12:43pm ET
 -0.93 / -4.13%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

No recent news for Loncar Cancer Immunotherapy ETF.


1 month-3.29% 3 years-0.50%
3 months+2.89% 5 years--
1 year+4.18% Since inception-1.95%
Data through 02/22/2020

Quote Details

Previous close$22.50
Open day’s range21.52 – 21.91
Net asset value (NAV)22.53 (02/21/2020)
Daily volume4,902
Average volume (3 months)14,492
Data as of 12:43pm ET, 02/24/2020

Peer Comparisonvs. Health ETFs

Performance 5-yr return--+8.75%
Expense Gross exp ratio0.79%1.26%
Risk 5 year sharpe ratio--0.45
Net assets$34.8M$3.2B
Average market cap$4.9B$41.2B
Average P/E--26.7
Dividend / Share--0.30%


VHT Vanguard Health Care Index Fund ETF Shar...
FHLC Fidelity MSCI Health Care Index ETF
IXJ iShares Global Healthcare ETF


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
FATE Fate Therapeutics Inc5.78%
MRNA Moderna Inc4.79%
ZYME Zymeworks Inc4.41%
YMAB Y-mAbs Therapeutics, Inc4.40%
AZN AstraZeneca4.38%
BMY Bristol-Myers Squibb4.27%
BNTX BioNTech SE4.23%
CLLS Cellectis SA4.17%
MRK Merck4.14%
BLUE bluebird bio Inc4.11%